Samah W Al-Jabi1, Sa'ed H Zyoud1,2,3, Waleed M Sweileh4, Aysha H Wildali5, Hanan M Saleem5, Hayat A Aysa5, Mohammad A Badwan5, Rahmat Awang3. 1. Department of Clinical and Community, Pharmacy College of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine. 2. Poison Control and Drug Information Center (PCDIC), College of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine. 3. WHO Collaborating Centre for Drug Information, National Poison Centre, Universiti Sains Malaysia (USM), Penang, Malaysia. 4. Department of Pharmacology and Toxicology, College of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine. 5. PharmD Program, College of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine.
Abstract
BACKGROUND: Evaluation of the association between treatment satisfaction and health-related quality of life (HRQoL) may enable health-care providers to understand the issues that influence quality of life and to recognize the aspects of hypertension treatment that need improvement to enhance the long-term treatment outcomes. OBJECTIVE: The aim of this study was to determine the relationship between HRQoL and treatment satisfaction in a sample of Palestinian hypertensive patients. METHODS: A cross-sectional study was conducted, adopting the Treatment Satisfaction Questionnaire for Medication (TSQM 1.4) for the assessment of treatment satisfaction and using the European Quality of Life scale (EQ-5D-5L) for the assessment of HRQoL. Descriptive and comparative statistics were used to describe socio-demographic and disease-related characteristics of the patients. All analyses were performed using SPSS v 15.0. RESULTS: Four hundred and ten hypertensive patients were enrolled in the study. This study findings indicate a positive correlation between all satisfaction domains and HRQoL. Significant differences were observed between this study variables (P < 0.001). After adjustment for covariates using multiple linear regression, an increase of one point in the global satisfaction scale was associated with a 0.16 increase in EQ-5D index scores (r = 0.16; P < 0.001). CONCLUSIONS: Patients with reportedly higher satisfaction scores have reported relatively higher EQ-5D-5L index values. These study findings could be helpful in clinical practice, mainly in the early treatment of hypertensive patients, at a point where improving treatment satisfaction and HRQoL is still possible.
BACKGROUND: Evaluation of the association between treatment satisfaction and health-related quality of life (HRQoL) may enable health-care providers to understand the issues that influence quality of life and to recognize the aspects of hypertension treatment that need improvement to enhance the long-term treatment outcomes. OBJECTIVE: The aim of this study was to determine the relationship between HRQoL and treatment satisfaction in a sample of Palestinian hypertensivepatients. METHODS: A cross-sectional study was conducted, adopting the Treatment Satisfaction Questionnaire for Medication (TSQM 1.4) for the assessment of treatment satisfaction and using the European Quality of Life scale (EQ-5D-5L) for the assessment of HRQoL. Descriptive and comparative statistics were used to describe socio-demographic and disease-related characteristics of the patients. All analyses were performed using SPSS v 15.0. RESULTS: Four hundred and ten hypertensivepatients were enrolled in the study. This study findings indicate a positive correlation between all satisfaction domains and HRQoL. Significant differences were observed between this study variables (P < 0.001). After adjustment for covariates using multiple linear regression, an increase of one point in the global satisfaction scale was associated with a 0.16 increase in EQ-5D index scores (r = 0.16; P < 0.001). CONCLUSIONS:Patients with reportedly higher satisfaction scores have reported relatively higher EQ-5D-5L index values. These study findings could be helpful in clinical practice, mainly in the early treatment of hypertensivepatients, at a point where improving treatment satisfaction and HRQoL is still possible.
Authors: N Langebeek; H G Sprenger; E H Gisolf; P Reiss; M A G Sprangers; Jc Legrand; C Richter; P T Nieuwkerk Journal: HIV Med Date: 2013-11-11 Impact factor: 3.180
Authors: Murtuza Bharmal; Krista Payne; Mark J Atkinson; Marie-Pierre Desrosiers; Donald E Morisky; Eric Gemmen Journal: Health Qual Life Outcomes Date: 2009-04-27 Impact factor: 3.186
Authors: Hubert Chen; Erika B Rosenzweig; S Karl Gotzkowsky; Carl Arneson; Andrew C Nelsen; Robert C Bourge Journal: Health Qual Life Outcomes Date: 2013-03-06 Impact factor: 3.186
Authors: Paola S Calles-Monar; María R Sanabria; Ana M Alonso-Tarancon; Rosa M Coco-Martin; Agustín Mayo-Iscar Journal: Drugs Aging Date: 2022-04-29 Impact factor: 3.923
Authors: Eba'a Hafi; Ro'ya Soradi; Sarah Diab; Ahmad M Samara; Marah Shakhshir; Malik Alqub; Sa'ed H Zyoud Journal: J Health Popul Nutr Date: 2021-07-05 Impact factor: 2.000
Authors: Sa'ed H Zyoud; Dala N Daraghmeh; Diana O Mezyed; Razan L Khdeir; Mayas N Sawafta; Nora A Ayaseh; Ghada H Tabeeb; Waleed M Sweileh; Rahmat Awang; Samah W Al-Jabi Journal: BMC Nephrol Date: 2016-04-27 Impact factor: 2.388
Authors: Sa'ed H Zyoud; Samah W Al-Jabi; Waleed M Sweileh; Diana A Arandi; Sujood A Dabeek; Hiba H Esawi; Remà H Atyeh; Hadeel A Abu-Ali; Yazan I Sleet; Baraa M Abd-Alfatah; Rahmat Awang Journal: J Clin Transl Endocrinol Date: 2015-03-31